BioTuesdays

Category - Markets

Galena Biopharma

Maxim ups Galena Biopharma price target to $4

Maxim Group raised its price target for Galena Biopharma (NASDAQ:GALE) to $4 from $1, saying the company has multiple programs moving forward, including NeuVax. The stock was quoted at $2.90 in afternoon trading on Dec...

Stellar Biotechnologies

Maxim cuts Stellar price target to $4

Maxim Group reduced its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $4 from $7, saying demand for the company’s keyhole limpet hemocyanin (KLH) is a slow climb. The stock was quoted at $2.59 at midday Dec...

Aradigm

Ladenburg cuts Aradigm price target to $7.50

Ladenburg Thalmann slashed its price target for Aradigm (NASDAQ:ARDM) to $7.50 from $26 but maintained its “buy” rating after the company reported mixed top-line Phase 3 results for Pulmaquin for the treatment of non...

Inotek Pharmaceuticals

Roth starts Inotek Pharma at buy

Roth Capital Partners initiated coverage of Inotek Pharmaceuticals (NASDAQ:ITEK) with a “buy” rating and $10 price target. The stock closed at $6.40 on Nov. 30. “In our opinion, Inotek’s trabodenoson has the...

Bellicum Pharmaceuticals

Ladenburg starts Bellicum Pharma at buy

Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29. Bellicum is developing novel cellular immunotherapies for...

Arrowhead Pharmaceuticals

WB downgrades Arrowhead Pharma to MP

William Blair downgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “market perform” from “outperform” and slashed its price target to $2 from $12. The stock closed at $4.39 on Tuesday. After markets closed on Nov. 29...

Aclaris Therapeutics

Leerink starts Aclaris at OP

Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $54 price target. The stock closed at $28.04 on Monday. Analyst Seamus Fernandez writes that the company’s lead asset, A...

Nivalis Therapeutics

Stifel downgrades Nivalis to hold

Stifel downgraded Nivalis Therapeutics (NASDAQ:NVLS) to “ hold” from “buy” and slashed its price target to $3.25 from $16 after the company released Phase 2 data for cavosonstat in the treatment of patients with...

Bovie Medical

Piper starts Bovie Medical at overweight

Piper Jaffray initiated coverage of Bovie Medical (NYSE:BVX) with an “overweight” rating and $6 price target. The stock closed at $4.24 on Friday. Bovie is best known within the operating room for its electrocautery...

Profound Medical Logo

Mackie ups Profound Medical price target to $4.40

Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday. Analyst Andre Uddin writes that...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.